Publications by authors named "Norma Porteiro"

Claim this Profile
E
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.
Ezequiel Cordova, Jeniffer Hernandez Rendon, Veronica Mingrone, Patricio Martin, Gisela Arevalo Calderon, Norma Porteiro

Lancet HIV· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, Norma Porteiro

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment.
Susan Swindells, Thomas Lutz, Lelanie Van Zyl, Norma Porteiro, Matthias Stoll

AIDS· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and epidemiological features of chronic Trypanosoma cruzi infection in patients with HIV/AIDS in Buenos Aires, Argentina.
Andrés Guillermo Benchetrit, Marisa Fernández, Amadeo Javier Bava, Marcelo Corti, Norma Porteiro

Int J Infect Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley

Lancet HIV· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, Argentina].
Ezequiel Córdova, Norma Porteiro, Eliana Loiza, Horacio Mingrone

Rev Chilena Infectol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Sarah Lilian Pett, Janaki Amin, Andrejz Horban, Jaime Andrade-Villanueva, Marcelo Losso, Norma Porteiro

Clin Infect Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina.
Ezequiel Córdova, Eliana Loiza, Norma Porteiro, Horacio Mingrone

Enferm Infecc Microbiol Clin· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis